Jardiance (empagliflozin)

pCPA File Number: 20874

Negotiation Status:

Concluded with an LOI

Indication(s):

Diabetes Mellitus, Type 2 with high cardiovascular risk

Sponsor/Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

CADTH Project Number:

SR0427-000

pCPA Engagement Letter Issued:

2016-03-03

Negotiation Process Concluded:

2016-04-13